Shares of BMO have fallen 2.7% to $59.99, while Marshall & Ilsley has surged by 23.8% to $7.17.
European regulators breathed new life into
Friday, recommending the approval of the company's drug Esbriet as a treatment for the fatal lung disease idiopathic pulmonary fibrosis.
Shares of the company surged by 113.5% to $30.47 in premarket trading Friday.
( MEE) is exploring options ranging from a sale of the company to a takeover of
International Coal Group
Massey shares were flat at $50.70, while International Coal has popped by 5.9% to $7.39.
posted fiscal second-quarter adjusted profit of $2.6 billion, or 51 cents a share, on revenue of $8.65 billion for the quarter ended Nov. 30. The performance topped the average estimate of analysts polled by Thomson Reuters for earnings of 46 cents a share on revenue of $8.34 billion.
Shares of the company popped by 4.1% to $31.52 in premarket trading.
Research In Motion
( RIMM) said it earned $911.1 million, or $1.74 a share, in its fiscal third quarter. The per-share figure was up 58% from its profit of $1.10 a share in the same period a year earlier and a dime above the average estimate of analysts polled by Thomson Reuters for earnings of $1.64 a share.
Shares of Research In Motion rose 2.7% to $60.85.
lifted its full-year forecast to earnings of $3.08 to $3.16 a share on a revenue increase of 8% to 11% vs. previously expected earnings of $3 to $3.08 a share on a revenue increase of 7% to 10%. Revenue for the current quarter is expected to be in the range of $5.6 billion to $5.8 billion, vs. the analyst consensus of $5.58 billion.
Accenture shares rose 4.2% to $48.62.
have regained their footing after plummeting on the
issuance of two alternative fee structures in determining "reasonable and proportional" debit interchange fees -- each of which suggesting a fee cap of 12 cents a transaction.
Shares of MasterCard rose 2.2% to $228.29, while Visa was up 1.9% to $68.47.
wasn't able to obtain approval for its heart medicine Brilinta from the Food and Drug Administration, which has asked for more analysis on clinical trial results.
Shares of the company fell 5.4% to $46.58.
-- Written by Andrea Tse in New York.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Copyright 2010 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.